Targeting DNA topoisomerase II in cancer chemotherapy

被引:1362
|
作者
Nitiss, John L. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Med Pharmacol, Memphis, TN 38105 USA
关键词
DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; END-JOINING PATHWAYS; RECEPTOR-ALPHA GENES; SACCHAROMYCES-CEREVISIAE; COVALENT COMPLEXES; CELL-CYCLE; HOMOLOGOUS RECOMBINATION;
D O I
10.1038/nrc2607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent molecular studies have expanded the biological contexts in which topoisomerase 11 (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation. Although the biological functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy. The molecular tools that have allowed an understanding of the biological functions of TOP2 are also being applied to understanding the details of drug action. These studies promise refined targeting of TOP2 as an effective anticancer strategy.
引用
收藏
页码:338 / 350
页数:13
相关论文
共 50 条
  • [1] Targeting DNA topoisomerase II in cancer chemotherapy
    John L. Nitiss
    Nature Reviews Cancer, 2009, 9 : 338 - 350
  • [2] Targeting DNA Topoisomerase II in Antifungal Chemotherapy
    Kondaka, Kavya
    Gabriel, Iwona
    MOLECULES, 2022, 27 (22):
  • [3] DNA topoisomerase II as a target for cancer chemotherapy
    Walker, JV
    Nitiss, JL
    CANCER INVESTIGATION, 2002, 20 (04) : 570 - 589
  • [4] DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
    Chikamori, K.
    Grozav, A. G.
    Kozuki, T.
    Grabowski, D.
    Ganapathi, R.
    Ganapathi, M. K.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (07) : 758 - 771
  • [5] Smart anti-cancer chemotherapy with selective DNA topoisomerase-targeting
    Li, Tsaikun
    Yeh, Yenhsui
    Chang, Tingkang
    Lee, Yeeshin
    CANCER SCIENCE, 2023, 114 : 735 - 735
  • [6] DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
    MacGrogan, G
    Rudolph, P
    de Mascarel, I
    Mauriac, L
    Durand, M
    Avril, A
    Dilhuydy, JM
    Robert, J
    Mathoulin-Pélissier, S
    Picot, V
    Floquet, A
    Sierankowski, G
    Coindre, JM
    BRITISH JOURNAL OF CANCER, 2003, 89 (04) : 666 - 671
  • [7] DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
    G MacGrogan
    P Rudolph
    I de Mascarel
    L Mauriac
    M Durand
    A Avril
    J M Dilhuydy
    J Robert
    S Mathoulin-Pélissier
    V Picot
    A Floquet
    G Sierankowski
    J M Coindre
    British Journal of Cancer, 2003, 89 : 666 - 671
  • [8] DNA TOPOISOMERASE-I AND TOPOISOMERASE-II IN CANCER-CHEMOTHERAPY - UPDATE AND PERSPECTIVES
    POMMIER, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (02) : 103 - 108
  • [9] Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer
    Dingemans, AMC
    Witlox, MA
    Stallaert, RALM
    van der Valk, P
    Postmus, PE
    Giaccone, G
    CLINICAL CANCER RESEARCH, 1999, 5 (08) : 2048 - 2058
  • [10] DNA topoisomerase II, genotoxicity, and cancer
    McClendon, A. Kathleen
    Osheroff, Neil
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2007, 623 (1-2) : 83 - 97